Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$406.88

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $386.88 24
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922027853?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $406.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $27.4408/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774067 CMS
Astellas Pharma US Inc $15.0007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821507199 CMS
Kowa Pharmaceuticals America, Inc. $12.0607/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805560179 CMS
SANOFI-AVENTIS U.S. LLC $17.4807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843460929 CMS
AbbVie Inc. $20.4707/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774063 CMS
AbbVie Inc. $15.9907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774059 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5507/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685814 CMS
Teva Pharmaceuticals USA, Inc. $18.3807/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839673591 CMS
IBSA Pharma Inc. $13.1306/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792515161 CMS
PFIZER INC. $20.0006/03/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833592637 CMS
Teva Pharmaceuticals USA, Inc. $14.1506/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839673587 CMS
Kowa Pharmaceuticals America, Inc. $15.3705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805560173 CMS
AbbVie Inc. $11.6005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774055 CMS
AbbVie Inc. $15.1905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774051 CMS
Lilly USA, LLC $11.1504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818994469 CMS
AbbVie Inc. $10.6104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774047 CMS
AbbVie Inc. $13.9004/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774043 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.3803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685816 CMS
PFIZER INC. $16.8603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833462559 CMS
AbbVie Inc. $18.2003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795774039 CMS
Novo Nordisk Inc $15.4402/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810881476 CMS
Novo Nordisk Inc $24.2602/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810921759 CMS
Lilly USA, LLC $15.6202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818988343 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.2201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820174343 CMS
Lilly USA, LLC $12.4301/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818899861 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

875 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,296.75 12/21/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671671983
Principal investigator 1 PFIZER INC. $8,786.06 12/20/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671677663
Principal investigator 1 PFIZER INC. $201.50 12/19/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671666643
Principal investigator 1 PFIZER INC. $2,560.25 12/18/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671674289
Principal investigator 1 PFIZER INC. $4,179.50 12/05/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671666361
Principal investigator 1 PFIZER INC. $18,308.91 12/05/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673399
Principal investigator 1 PFIZER INC. $1,061.90 12/05/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675089
Principal investigator 1 PFIZER INC. $563.16 12/05/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685789
Principal investigator 1 PFIZER INC. $2,645.00 12/04/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS No dispute reported 06/30/2026 671657051
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816647
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816649
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816651
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816653
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816655
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816657
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816659
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816661
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816663
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816665
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816667
Principal investigator 1 Emergent BioSolutions Inc. $777.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816669
Principal investigator 1 Emergent BioSolutions Inc. $777.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816671
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816673
Principal investigator 1 Emergent BioSolutions Inc. $777.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816675
Principal investigator 1 Emergent BioSolutions Inc. $777.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816677
Principal investigator 1 Emergent BioSolutions Inc. $777.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816679
Principal investigator 1 Emergent BioSolutions Inc. $762.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816681
Principal investigator 1 Emergent BioSolutions Inc. $762.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816683
Principal investigator 1 Emergent BioSolutions Inc. $762.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816685
Principal investigator 1 Emergent BioSolutions Inc. $762.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816687
Principal investigator 1 Emergent BioSolutions Inc. $762.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816689
Principal investigator 1 Emergent BioSolutions Inc. $697.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816691
Principal investigator 1 Emergent BioSolutions Inc. $697.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816693
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816695
Principal investigator 1 Emergent BioSolutions Inc. $628.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816697
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816699
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816701
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816703
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816705
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816707
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816709
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816711
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816713
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816715
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816717
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816719
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816721
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816723
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816725
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816727
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816729
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816731
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816733
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816735
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816737
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816739
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816741
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816743
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816745
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816747
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816749
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816751
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816753
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816755
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816757
Principal investigator 1 Emergent BioSolutions Inc. $563.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816759
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816761
Principal investigator 1 Emergent BioSolutions Inc. $447.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816763
Principal investigator 1 Emergent BioSolutions Inc. $447.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816765
Principal investigator 1 Emergent BioSolutions Inc. $447.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816767
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816769
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816771
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816773
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816775
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816777
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816779
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816781
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816783
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816785
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816787
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816789
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816791
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816793
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816795
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816797
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816799
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816801
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816803
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816805
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816807
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816809
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816811
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816813
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816815
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816817
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816819
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816821
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816823
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816825
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816827
Principal investigator 1 Emergent BioSolutions Inc. $1,658.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816829
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816831
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816833
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816835
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816837
Principal investigator 1 Emergent BioSolutions Inc. $1,311.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816839
Principal investigator 1 Emergent BioSolutions Inc. $1,311.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816841
Principal investigator 1 Emergent BioSolutions Inc. $1,311.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816843
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816845
Principal investigator 1 Emergent BioSolutions Inc. $1,311.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816847
Principal investigator 1 Emergent BioSolutions Inc. $1,311.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816849
Principal investigator 1 Emergent BioSolutions Inc. $1,311.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816851
Principal investigator 1 Emergent BioSolutions Inc. $1,279.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816853
Principal investigator 1 Emergent BioSolutions Inc. $1,279.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816855
Principal investigator 1 Emergent BioSolutions Inc. $1,279.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816857
Principal investigator 1 Emergent BioSolutions Inc. $1,279.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816859
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816861
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816863
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816865
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816867
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816869
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816871
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816873
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816875
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816877
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816879
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816881
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816883
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816885
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816887
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816889
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816891
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816893
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816895
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816897
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816899
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816901
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816903
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816905
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816907
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816909
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816911
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816913
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816915
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816917
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816919
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816921
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816923
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816925
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816927
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816929
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816931
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816933
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816935
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816937
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816939
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816941
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816943
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816945
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816947
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816949
Principal investigator 1 Emergent BioSolutions Inc. $854.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816951
Principal investigator 1 Emergent BioSolutions Inc. $1,846.56 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687816953
Principal investigator 1 Ferring International Pharmascience Center US $2,059.20 12/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228551
Principal investigator 1 Merck Sharp & Dohme Corporation $8,880.00 11/26/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691449501
Principal investigator 1 PFIZER INC. $12,998.40 11/23/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671674487
Principal investigator 1 PFIZER INC. $1,491.88 11/22/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666363
Principal investigator 1 PFIZER INC. $1,407.90 11/22/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685857
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813757
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813759
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813761
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813763
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813765
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813767
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813769
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813771
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813773
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813775
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813777
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813779
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813781
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813783
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813785
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813787
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813789
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813791
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813793
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813795
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813797
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813799
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813801
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813803
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813805
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813807
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813809
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813811
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813813
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813815
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813817
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813819
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813821
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813823
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813825
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813827
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813829
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813831
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813833
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813835
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813837
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813839
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813841
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813843
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813845
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813847
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813849
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813851
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813853
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813855
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813857
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813859
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813861
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813863
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813865
Principal investigator 1 Emergent BioSolutions Inc. $777.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813867
Principal investigator 1 Emergent BioSolutions Inc. $777.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813869
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813871
Principal investigator 1 Emergent BioSolutions Inc. $777.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813873
Principal investigator 1 Emergent BioSolutions Inc. $777.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813875
Principal investigator 1 Emergent BioSolutions Inc. $777.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813877
Principal investigator 1 Emergent BioSolutions Inc. $762.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813879
Principal investigator 1 Emergent BioSolutions Inc. $762.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813881
Principal investigator 1 Emergent BioSolutions Inc. $697.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813883
Principal investigator 1 Emergent BioSolutions Inc. $697.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813885
Principal investigator 1 Emergent BioSolutions Inc. $697.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813887
Principal investigator 1 Emergent BioSolutions Inc. $697.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813889
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813891
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813893
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813895
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813897
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813899
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813901
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813903
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813905
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813907
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813909
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813911
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813913
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813915
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813917
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813919
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813921
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813923
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813925
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813927
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813929
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813931
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813933
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813935
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813937
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813939
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813941
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813943
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813945
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813947
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813949
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813951
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813953
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813955
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813957
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813959
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813961
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813963
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813965
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813967
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813969
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813971
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813973
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813975
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813977
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813979
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813981
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813983
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813985
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813987
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813989
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813991
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813993
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813995
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813997
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813999
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814001
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814003
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814005
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814007
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814009
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814011
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814013
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814015
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814017
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814019
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814021
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814023
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814025
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814027
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814029
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814031
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814033
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814035
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814037
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814039
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814041
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814043
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814045
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814047
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814049
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814051
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814053
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814055
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814057
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814059
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814061
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814063
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814065
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814067
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814069
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814071
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814073
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814075
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814077
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814079
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814081
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814083
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814085
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814087
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814089
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814091
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814093
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814095
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814097
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814099
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814101
Principal investigator 1 Emergent BioSolutions Inc. $1,907.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814103
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814105
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814107
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814109
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814111
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814113
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814115
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814117
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814119
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814121
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814123
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814125
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814127
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814129
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814131
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814133
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814135
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814137
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814139
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814141
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814143
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814145
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814147
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814149
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814151
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814153
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814155
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814157
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814159
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814161
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814163
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814165
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814167
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814169
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814171
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814173
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814175
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814177
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814179
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814181
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814183
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814185
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814187
Principal investigator 1 Emergent BioSolutions Inc. $1,987.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814189
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814191
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814193
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814195
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814197
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814199
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814201
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814203
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814205
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814207
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814209
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814211
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814213
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814215
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814217
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814219
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814221
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814223
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814225
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814227
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814229
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814231
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814233
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814235
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814237
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814239
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814241
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814243
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814245
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814247
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814249
Principal investigator 1 Emergent BioSolutions Inc. $1,074.56 11/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687814251
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812911
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812913
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812915
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812917
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812919
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812921
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812923
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812925
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812927
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812929
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812931
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812933
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812935
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812937
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812939
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812941
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812943
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812945
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812947
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812949
Principal investigator 1 Emergent BioSolutions Inc. $1,056.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812951
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812953
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812955
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812957
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812959
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812961
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812963
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812965
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812967
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812969
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812971
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812973
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812975
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812977
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812979
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812981
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812983
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812985
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812987
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812989
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812991
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812993
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812995
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812997
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812999
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813001
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813003
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813005
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813007
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813009
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813011
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813013
Principal investigator 1 Emergent BioSolutions Inc. $854.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813015
Principal investigator 1 Emergent BioSolutions Inc. $762.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813017
Principal investigator 1 Emergent BioSolutions Inc. $697.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813019
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813021
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813023
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813025
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813027
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813029
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813031
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813033
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813035
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813037
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813039
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813041
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813043
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813045
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813047
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813049
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813051
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813053
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813055
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813057
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813059
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813061
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813063
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813065
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813067
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813069
Principal investigator 1 Emergent BioSolutions Inc. $628.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813071
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813073
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813075
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813077
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813079
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813081
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813083
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813085
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813087
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813089
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813091
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813093
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813095
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813097
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813099
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813101
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813103
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813105
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813107
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813109
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813111
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813113
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813115
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813117
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813119
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813121
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813123
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813125
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813127
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813129
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813131
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813133
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813135
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813137
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813139
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813141
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813143
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813145
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813147
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813149
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813151
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813153
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813155
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813157
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813159
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813161
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813163
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813165
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813167
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813169
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813171
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813173
Principal investigator 1 Emergent BioSolutions Inc. $563.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813175
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813177
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813179
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813181
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813183
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813185
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813187
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813189
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813191
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813193
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813195
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813197
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813199
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813201
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813203
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813205
Principal investigator 1 Emergent BioSolutions Inc. $447.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813207
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813209
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813211
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813213
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813215
Principal investigator 1 Emergent BioSolutions Inc. $1,882.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813217
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813219
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813221
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813223
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813225
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813227
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813229
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813231
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813233
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813235
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813237
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813239
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813241
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813243
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813245
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813247
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813249
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813251
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813253
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813255
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813257
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813259
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813261
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813263
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813265
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813267
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813269
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813271
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813273
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813275
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813277
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813279
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813281
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813283
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813285
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813287
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813289
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813291
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813293
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813295
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813297
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813299
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813301
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813303
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813305
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813307
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813309
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813311
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813313
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813315
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813317
Principal investigator 1 Emergent BioSolutions Inc. $1,379.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813319
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813321
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813323
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813325
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813327
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813329
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813331
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813333
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813335
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813337
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813339
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813341
Principal investigator 1 Emergent BioSolutions Inc. $1,179.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813343
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813345
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813347
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813349
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813351
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813353
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813355
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813357
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813359
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813361
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813363
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813365
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813367
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813369
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813371
Principal investigator 1 Emergent BioSolutions Inc. $1,111.56 11/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687813373
Principal investigator 1 PFIZER INC. $438.00 11/07/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671667457
Principal investigator 1 PFIZER INC. $1,465.00 11/02/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671666735
Principal investigator 1 PFIZER INC. $8,664.52 11/02/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671674367
Principal investigator 1 PFIZER INC. $281.58 11/02/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685921
Principal investigator 1 Emergent BioSolutions Inc. $2,413.56 11/01/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687812535
Principal investigator 1 PFIZER INC. $13,429.50 11/01/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666741
Principal investigator 1 PFIZER INC. $2,500.00 11/01/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS No dispute reported 06/30/2026 671666915
Principal investigator 1 PFIZER INC. $23.75 10/31/2019 Non-covered Recipient Entity
Avail Clinical Research LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671672929
Principal investigator 1 Merck Sharp & Dohme Corporation $29,745.00 10/24/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691336409
Principal investigator 1 PFIZER INC. $10,528.40 10/23/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672579
Principal investigator 1 PFIZER INC. $2,252.64 10/23/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685791
Principal investigator 1 Merck Sharp & Dohme Corporation $3,440.00 10/22/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691337957
Principal investigator 1 PFIZER INC. $6,400.00 10/22/2019 Non-covered Recipient Entity
University Clinical Research LLC dba Avail Clinical Research LLC
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 671666739
Principal investigator 1 PFIZER INC. $2,687.36 10/22/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666835
Principal investigator 1 PFIZER INC. $1,750.00 10/19/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671673713
Principal investigator 1 PFIZER INC. $118.75 10/17/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671667455
Principal investigator 1 GlaxoSmithKline, LLC. $29,350.69 10/16/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 669967275
Principal investigator 1 Boehringer Ingelheim International GmbH $0.39 10/15/2019 Non-covered Recipient Entity
AVAIL CLNICAL RSRCH
Comparative study in Psoriasis No dispute reported 06/30/2026 703927895
Principal investigator 1 American Regent $6,100.00 10/09/2019 Non-covered Recipient Entity
University Clinical Rsearch - Deland, Llc
Heart_FID No dispute reported 06/30/2026 681797215
Principal investigator 1 Horizon Therapeutics plc $9,744.25 10/09/2019 Non-covered Recipient Entity
AVAIL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA PEGLOTICASE MIRROR RANDOMIZED CONTROLLED TRIAL RCT No dispute reported 06/30/2026 684001185
Principal investigator 1 PFIZER INC. $563.16 10/09/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685455
Principal investigator 1 PFIZER INC. $1,373.32 10/09/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685787
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810967
Principal investigator 1 Emergent BioSolutions Inc. $1,947.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810969
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810971
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810973
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810975
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810977
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810979
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810981
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810983
Principal investigator 1 Emergent BioSolutions Inc. $1,216.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810985
Principal investigator 1 Emergent BioSolutions Inc. $1,119.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810987
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810989
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810991
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810993
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810995
Principal investigator 1 Emergent BioSolutions Inc. $1,079.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810997
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687810999
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811001
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811003
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811005
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811007
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811009
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811011
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811013
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811015
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811017
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811019
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811021
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811023
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811025
Principal investigator 1 Emergent BioSolutions Inc. $1,034.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811027
Principal investigator 1 Emergent BioSolutions Inc. $563.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811029
Principal investigator 1 Emergent BioSolutions Inc. $563.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811031
Principal investigator 1 Emergent BioSolutions Inc. $563.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811033
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811035
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811037
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811039
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811041
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811043
Principal investigator 1 Emergent BioSolutions Inc. $1,809.56 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687811045
Principal investigator 1 GlaxoSmithKline, LLC. $93,254.82 10/04/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 669968285
Principal investigator 1 PFIZER INC. $9,602.14 10/04/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670245
Principal investigator 1 PFIZER INC. $8,298.08 10/03/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666737
Principal investigator 1 PFIZER INC. $2,250.00 10/03/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671673881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68,500.00 10/03/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects No dispute reported 06/30/2026 639737453
Principal investigator 1 Ferring International Pharmascience Center US $1,488.60 10/02/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228277
Principal investigator 1 Emergent BioSolutions Inc. $3,836.56 10/01/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687807961
Principal investigator 1 Merck Sharp & Dohme Corporation $50,385.00 09/26/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691334263
Principal investigator 1 PFIZER INC. $14,295.17 09/20/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673025
Principal investigator 1 PFIZER INC. $1,057.16 09/20/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685855
Principal investigator 1 PFIZER INC. $1,737.50 09/19/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671674625
Principal investigator 1 Merck Sharp & Dohme Corporation $339.75 09/16/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691356119
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 09/13/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691515861
Principal investigator 1 Merck Sharp & Dohme Corporation $372.00 09/12/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691515377
Principal investigator 1 Emergent BioSolutions Inc. $5,575.56 09/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687803147
Principal investigator 1 Emergent BioSolutions Inc. $1,675.56 09/11/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 687803149
Principal investigator 1 PFIZER INC. $110.88 09/11/2019 Non-covered Recipient Entity
Avail Clinical
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 671645379
Principal investigator 1 PFIZER INC. $35.20 09/11/2019 Non-covered Recipient Entity
Avail Clinical
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 671645381
Principal investigator 1 PFIZER INC. $113.95 09/11/2019 Non-covered Recipient Entity
Avail Clinical
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 671645403
Principal investigator 1 PFIZER INC. $120.35 09/11/2019 Non-covered Recipient Entity
Avail Clinical
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 671645563
Principal investigator 1 PFIZER INC. $212.38 09/11/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671671625
Principal investigator 1 GlaxoSmithKline, LLC. $2,593.20 09/03/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
ZOSTER-056 No dispute reported 06/30/2026 669975051
Principal investigator 1 Merck Sharp & Dohme Corporation $386.34 08/28/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691410911
Principal investigator 1 PFIZER INC. $8,737.65 08/28/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671674817
Principal investigator 1 PFIZER INC. $514.50 08/28/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671676807
Principal investigator 1 PFIZER INC. $2,721.58 08/28/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685923
Principal investigator 1 GlaxoSmithKline, LLC. $7,200.00 08/27/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
ZOSTER-064 No dispute reported 06/30/2026 669962005
Principal investigator 1 PFIZER INC. $455.00 08/27/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666833
Principal investigator 1 Ferring International Pharmascience Center US $10,328.40 08/26/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228011
Principal investigator 1 Ferring International Pharmascience Center US $5,850.00 08/23/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227971
Principal investigator 1 Merck Sharp & Dohme Corporation $502.20 08/23/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691498413
Principal investigator 1 Noven Pharmaceuticals, Inc. $300.00 08/23/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS OA OF THE KNEE. No dispute reported 06/30/2026 675518985
Principal investigator 1 Merck Sharp & Dohme Corporation $24,045.00 08/22/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691346189
Principal investigator 1 Merck Sharp & Dohme Corporation $94.00 08/22/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691346203
Principal investigator 1 PFIZER INC. $890.00 08/22/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671667549
Principal investigator 1 PFIZER INC. $1,500.00 08/22/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671667551
Principal investigator 1 PFIZER INC. $6,698.27 08/20/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671668843
Principal investigator 1 PFIZER INC. $1,497.50 08/16/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671666919
Principal investigator 1 Merck Sharp & Dohme Corporation $193.17 08/15/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691410906
Principal investigator 1 PFIZER INC. $1,754.64 08/14/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666917
Principal investigator 1 PFIZER INC. $2,510.76 08/14/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669583
Principal investigator 1 PFIZER INC. $2,048.20 08/14/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671675559
Principal investigator 1 PFIZER INC. $1,051.88 08/14/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671677883
Principal investigator 1 Merck Sharp & Dohme Corporation $4,365.00 08/08/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691346191
Principal investigator 1 PFIZER INC. $219.00 08/08/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671667547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,475.00 08/08/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects No dispute reported 06/30/2026 639737451
Principal investigator 1 PFIZER INC. $2,500.00 08/07/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671667453
Principal investigator 1 PFIZER INC. $4,940.01 08/06/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670261
Principal investigator 1 PFIZER INC. $4,911.61 08/06/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685589
Principal investigator 1 PFIZER INC. $6,437.79 08/03/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666359
Principal investigator 1 Eli Lilly and Company $100.00 07/31/2019 Non-covered Recipient Entity
ACCORD CLINICAL RESEARCH LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654286713
Principal investigator 1 Merck Sharp & Dohme Corporation $558.00 07/30/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691509147
Principal investigator 1 Eli Lilly and Company $270.50 07/25/2019 Non-covered Recipient Entity
PHYSICIANS RESEARCH COLLABORATION
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654297131
Principal investigator 1 GlaxoSmithKline, LLC. $22,425.00 07/24/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
ZOSTER-064 No dispute reported 06/30/2026 669975719
Principal investigator 1 Merck Sharp & Dohme Corporation $7,500.00 07/23/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691346197
Principal investigator 1 Eli Lilly and Company $9,725.00 07/22/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A STUDY OF LY3372993 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE (AD) No dispute reported 06/30/2026 654297743
Principal investigator 1 PFIZER INC. $17,271.00 07/19/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS No dispute reported 06/30/2026 671657061
Principal investigator 1 PFIZER INC. $2,712.25 07/18/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666837
Principal investigator 1 PFIZER INC. $1,908.06 07/18/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671671901
Principal investigator 1 PFIZER INC. $5,063.52 07/18/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68,000.00 07/18/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects No dispute reported 06/30/2026 639737449
Principal investigator 1 PFIZER INC. $637.14 07/17/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671644501
Principal investigator 1 PFIZER INC. $6,937.00 07/13/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685859
Principal investigator 1 PFIZER INC. $2,053.10 07/10/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671644425
Principal investigator 1 PFIZER INC. $10,650.14 07/10/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671668205
Principal investigator 1 PFIZER INC. $5,440.19 07/10/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685925
Principal investigator 1 PFIZER INC. $1,908.06 07/09/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671670451
Principal investigator 1 PFIZER INC. $100.19 07/08/2019 Non-covered Recipient Entity
Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685451
Principal investigator 1 PFIZER INC. $754.11 07/02/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671644651
Principal investigator 1 PFIZER INC. $100.00 06/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671645471
Principal investigator 1 PFIZER INC. $100.00 06/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671645497
Principal investigator 1 PFIZER INC. $25.00 06/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671645531
Principal investigator 1 PFIZER INC. $25.00 06/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671645533
Principal investigator 1 PFIZER INC. $212.38 06/26/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671644497
Principal investigator 1 PFIZER INC. $5,120.50 06/26/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671644573
Principal investigator 1 Eli Lilly and Company $259.48 06/25/2019 Non-covered Recipient Entity
PHYSICIANS RESEARCH COLLABORATION
EVALUATION OF THE EFFECT OF MIRIKIZUMAB ON THE PHARMACOKINETICS OF CYTOCHROME P450 SUBSTRATES IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654296153
Principal investigator 1 PFIZER INC. $13,282.01 06/25/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685985
Principal investigator 1 PFIZER INC. $6,000.00 06/22/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671633043
Principal investigator 1 PFIZER INC. $4,600.39 06/22/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671644499
Principal investigator 1 PFIZER INC. $4,125.00 06/21/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS No dispute reported 06/30/2026 671626025
Principal investigator 1 PFIZER INC. $6,000.00 06/21/2019 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671633041
Principal investigator 1 PFIZER INC. $7,686.84 06/21/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 671635805
Principal investigator 1 PFIZER INC. $4,748.00 06/20/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671633009
Principal investigator 1 PFIZER INC. $512.05 06/19/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671644569
Principal investigator 1 PFIZER INC. $8,330.02 06/19/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671644649
Principal investigator 1 Merck Sharp & Dohme Corporation $1,352.19 06/10/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691411265
Principal investigator 1 Merck Sharp & Dohme Corporation $1,041.60 06/09/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691484851
Principal investigator 1 PFIZER INC. $512.05 06/05/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671644571
Principal investigator 1 PFIZER INC. $14,580.46 06/05/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685987
Principal investigator 1 Ferring International Pharmascience Center US $3,600.00 06/03/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227447
Principal investigator 1 PFIZER INC. $5,940.34 05/31/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625061
Principal investigator 1 PFIZER INC. $25.00 05/31/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671645473
Principal investigator 1 PFIZER INC. $100.00 05/31/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671645475
Principal investigator 1 PFIZER INC. $25.00 05/31/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671645477
Principal investigator 1 PFIZER INC. $100.00 05/31/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671645529
Principal investigator 1 PFIZER INC. $7,500.00 05/30/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS No dispute reported 06/30/2026 671626031
Principal investigator 1 PFIZER INC. $1,198.68 05/29/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625047
Principal investigator 1 PFIZER INC. $4,748.00 05/29/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671632763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $153,000.00 05/29/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects No dispute reported 06/30/2026 639737447
Principal investigator 1 PFIZER INC. $5,660.02 05/24/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685989
Principal investigator 1 PFIZER INC. $500.00 05/23/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671632765
Principal investigator 1 PFIZER INC. $3,525.68 05/23/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671633037
Principal investigator 1 PFIZER INC. $6,473.87 05/23/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685393
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/21/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691346193
Principal investigator 1 PFIZER INC. $300.57 05/20/2019 Non-covered Recipient Entity
Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685385
Principal investigator 1 PFIZER INC. $1,938.94 05/18/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625385
Principal investigator 1 Merck Sharp & Dohme Corporation $810.79 05/15/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691345375
Principal investigator 1 PFIZER INC. $16,814.44 05/11/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628593
Principal investigator 1 PFIZER INC. $811.72 05/08/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625063
Principal investigator 1 PFIZER INC. $1,000.00 05/08/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628611
Principal investigator 1 PFIZER INC. $20,544.23 05/08/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685457
Principal investigator 1 Merck Sharp & Dohme Corporation $5,500.00 05/07/2019 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691346195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,350.00 05/02/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects No dispute reported 06/30/2026 639737445
Principal investigator 1 PFIZER INC. $1,508.22 05/01/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625081
Principal investigator 1 PFIZER INC. $5,500.00 04/30/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625927
Principal investigator 1 PFIZER INC. $100.00 04/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671645499
Principal investigator 1 PFIZER INC. $25.00 04/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671645501
Principal investigator 1 PFIZER INC. $100.00 04/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671645503
Principal investigator 1 PFIZER INC. $25.00 04/30/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671645535
Principal investigator 1 PFIZER INC. $400.76 04/29/2019 Non-covered Recipient Entity
Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685453
Principal investigator 1 PFIZER INC. $9,027.85 04/24/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685389
Principal investigator 1 PFIZER INC. $5,940.34 04/19/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671624953
Principal investigator 1 PFIZER INC. $7,222.28 04/19/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685459
Principal investigator 1 PFIZER INC. $16,261.62 04/18/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671632795
Principal investigator 1 PFIZER INC. $524.05 04/12/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671633039
Principal investigator 1 PFIZER INC. $7,848.40 04/10/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671624613
Principal investigator 1 PFIZER INC. $3,151.47 04/10/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628609
Principal investigator 1 PFIZER INC. $2,232.00 04/10/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671632761
Principal investigator 1 PFIZER INC. $400.76 04/10/2019 Non-covered Recipient Entity
Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685387
Principal investigator 1 PFIZER INC. $5,599.00 04/10/2019 Non-covered Recipient Entity
Avail Clinical Research dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $183,175.00 04/10/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects No dispute reported 06/30/2026 639737443
Principal investigator 1 PFIZER INC. $5,599.00 04/09/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685461
Principal investigator 1 PFIZER INC. $9,787.34 04/06/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625065
Principal investigator 1 PFIZER INC. $599.34 03/27/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628579
Principal investigator 1 Eli Lilly and Company $371.50 03/26/2019 Non-covered Recipient Entity
PHYSICIANS RESEARCH COLLABORATION
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654297129
Principal investigator 1 Eli Lilly and Company $112,793.23 03/25/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
EVALUATION OF THE EFFECT OF MIRIKIZUMAB ON THE PHARMACOKINETICS OF CYTOCHROME P450 SUBSTRATES IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654298295
Principal investigator 1 PFIZER INC. $1,720.60 03/20/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628553
Principal investigator 1 PFIZER INC. $750.00 03/20/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628555
Principal investigator 1 Eli Lilly and Company $3,912.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY No dispute reported 06/30/2026 654298773
Principal investigator 1 Ferring Pharmaceuticals AS $250.00 03/18/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228965
Principal investigator 1 Eli Lilly and Company $1,138.40 03/15/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654298303
Principal investigator 1 PFIZER INC. $1,798.02 03/13/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628557
Principal investigator 1 Eli Lilly and Company $8.06 03/08/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654298301
Principal investigator 1 Horizon Therapeutics plc $75,572.50 03/06/2019 Non-covered Recipient Entity
AVAIL RESEARCH
A MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA PEGLOTICASE MIRROR OL No dispute reported 06/30/2026 684001135
Principal investigator 1 PFIZER INC. $771.75 03/06/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671628589
Principal investigator 1 Eli Lilly and Company $17,129.64 03/05/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654298981
Principal investigator 1 PFIZER INC. $1,353.45 03/04/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628591
Principal investigator 1 Ferring Pharmaceuticals AS $1,800.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228853
Principal investigator 1 PFIZER INC. $4,117.96 02/20/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624431
Principal investigator 1 PFIZER INC. $6,462.15 02/19/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628595
Principal investigator 1 PFIZER INC. $200.38 02/18/2019 Non-covered Recipient Entity
Accel Research Sites Clinical Research Unit
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685525
Principal investigator 1 PFIZER INC. $6,187.12 02/13/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624741
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $27,668.22 02/11/2019 Non-covered Recipient Entity
University Clinical Research
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to No dispute reported 06/30/2026 639754779
Principal investigator 1 PFIZER INC. $5,122.95 02/06/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671624433
Principal investigator 1 PFIZER INC. $4,677.68 02/04/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624583
Principal investigator 1 PFIZER INC. $6,147.05 02/04/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671624699
Principal investigator 1 PFIZER INC. $2,704.68 02/02/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628607
Principal investigator 1 Eli Lilly and Company $300.00 01/31/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654298537
Principal investigator 1 Eli Lilly and Company $4,189.00 01/28/2019 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654298039
Principal investigator 1 PFIZER INC. $2,451.48 01/24/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625341
Principal investigator 1 PFIZER INC. $279.04 01/22/2019 Non-covered Recipient Entity
Avail Clinical Research LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671625015
Principal investigator 1 PFIZER INC. $6,446.62 01/16/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625305
Principal investigator 1 PFIZER INC. $7,000.00 01/10/2019 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671625367
Principal investigator 1 PFIZER INC. $4,236.06 01/08/2019 Non-covered Recipient Entity
Avail Clinical Research
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671624345
Principal investigator 1 PFIZER INC. $2,583.50 01/04/2019 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 671624939